dc.creator | Macías Sánchez, Juan | es |
dc.creator | González Moreno, Paz | es |
dc.creator | Sánchez García, Esther | es |
dc.creator | Morillo Verdugo, Ramón Alejandro | es |
dc.creator | Pérez Venegas, José J. | es |
dc.creator | Pinilla, Ana | es |
dc.creator | Macho, M. Mar | es |
dc.creator | Martínez, M. Victoria | es |
dc.creator | González-Serna Martín, Manuel Alejandro | es |
dc.creator | Corma, Anaïs | es |
dc.creator | Real, Luis M. | es |
dc.creator | Pineda Vergara, Juan Antonio | es |
dc.date.accessioned | 2022-06-07T16:01:21Z | |
dc.date.available | 2022-06-07T16:01:21Z | |
dc.date.issued | 2021 | |
dc.identifier.citation | Macías Sánchez, J., González Moreno, P., Sánchez García, E., Morillo Verdugo, R.A., Pérez Venegas, J.J., Pinilla, A.,...,Pineda Vergara, J.A. (2021). Similar incidence of coronavirus disease 2019 (COVID-19) in patients with rheumatic diseases with and without hydroxychloroquine therapy. PLoS ONE, 16 (4), e0249036. | |
dc.identifier.issn | 1932-6203 | es |
dc.identifier.uri | https://hdl.handle.net/11441/134171 | |
dc.description.abstract | Background Hydroxychloroquine is not efficacious as post-exposure prophylaxis against coronavirus disease 2019 (COVID-19). It is not known whether as pre-exposure prophylaxis it may prevent COVID-19. Objective To compare the incidence of COVID-19 in Spanish patients with autoimmune rheumatic diseases treated with and without hydroxychloroquine. Patients and methods Retrospective electronic record review, from February 27th to June 21st, 2020, of patients with autoimmune inflammatory diseases followed at two academic tertiary care hospitals in Seville, Spain. The cumulative incidence of confirmed COVID-19, by PCR or serology, was compared between patients with and without hydroxychloroquine as part of their treatment of autoimmune inflammatory diseases. Results Among 722 included patients, 290 (40%) were receiving hydroxychloroquine. During the seventeen-week study period, 10 (3.4% [95% CI: 1.7%-6.7%] cases of COVID-19 were registered among patients with hydroxychloroquine and 13 (3.0% [1.6%-5.1%]) (p = 0.565) in those without hydroxychloroquine. COVID-19 was diagnosed by PCR in four (1.4%, 95% CI 0.38%-3.5%) subject with hydroxychloroquine and six (1.4%, 95% CI 0.5%-3.0%) without hydroxychloroquine (p = 0.697). Three patients on hydroxychloroquine and four patients without hydroxychloroquine were admitted to the hospital, none of them required to be transferred to the intensive care unit and no patient died during the episode. Conclusions The incidence and severity of COVID-19 among patients with autoimmune rheumatic diseases with and without hydroxychloroquine was not significantly different. | es |
dc.description.sponsorship | Instituto de Salud Carlos III I3SNS | es |
dc.description.sponsorship | Ministerio de Ciencia, Innovación y Universidades CP18/00146 | es |
dc.format | application/pdf | es |
dc.format.extent | 6 p. | es |
dc.language.iso | eng | es |
dc.publisher | Public Library of Science | es |
dc.relation.ispartof | PLoS ONE, 16 (4), e0249036. | |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.title | Similar incidence of coronavirus disease 2019 (COVID-19) in patients with rheumatic diseases with and without hydroxychloroquine therapy | es |
dc.type | info:eu-repo/semantics/article | es |
dcterms.identifier | https://ror.org/03yxnpp24 | |
dc.type.version | info:eu-repo/semantics/publishedVersion | es |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | es |
dc.contributor.affiliation | Universidad de Sevilla. Departamento de Farmacología | es |
dc.contributor.affiliation | Universidad de Sevilla. Departamento de Fisiología | es |
dc.contributor.affiliation | Universidad de Sevilla. Departamento de Medicina | es |
dc.relation.projectID | I3SNS | es |
dc.relation.projectID | CP18/00146 | es |
dc.relation.publisherversion | https://doi.org/10.1371/journal.pone.0249036 | es |
dc.identifier.doi | 10.1371/journal.pone.0249036 | es |
dc.journaltitle | PLoS ONE | es |
dc.publication.volumen | 16 | es |
dc.publication.issue | 4 | es |
dc.publication.initialPage | e0249036 | es |
dc.contributor.funder | Instituto de Salud Carlos III | es |
dc.contributor.funder | Ministerio de Ciencia, Innovación y Universidades (MICINN). España | es |